Physician profile
Mark E Friedel
NPI 1972708139
$2,804.70
in general payments reported to CMS, 2019-2025
22 companies · $566 in 2025
The $566 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $569 · 2020: $168 · 2021: $306 · 2022: $388 · 2023: $279 · 2024: $529 · 2025: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,374.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $582.93 | 2019-2025 | |
| Glaxosmithkline, LLC. | $427.80 | 2021-2025 | Nucala |
| Optinose US, INC. | $421.10 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $401.13 | 2019-2025 | Dupixent |
| Alk-Abello, INC | $197.03 | 2019-2022 | |
| Medtronic USA, INC. | $148.48 | 2019 | |
| Intersect Ent, INC. | $121.91 | 2019 | |
| Kaleo, INC. | $72.49 | 2019-2020 | |
| Aerin Medical INC. | $66.29 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $56.12 | 2021-2023 | |
| Stryker Corporation | $52.16 | 2019-2021 | |
| Incyte Corporation | $33.17 | 2025 | Opzelura |
| Astrazeneca Pharmaceuticals Lp | $30.60 | 2025 | Tezspire |
| Kerecis Limited | $29.40 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Greer Laboratories, INC. | $29.17 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $25.48 | 2024 | Arista Ah Flexitip |
| Medtronic, INC. | $24.31 | 2023 | Ligasure |
| Avadel Cns Pharmaceuticals, LLC | $18.61 | 2024 | Lumryz |
| Csl Behring | $17.96 | 2025 | Hizentra |
| Amgen INC. | $17.70 | 2025 | Tezspire |
| Ars Pharmaceuticals Operations, INC. | $17.00 | 2025 | Neffy |
| Acclarent, INC | $13.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Friedel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.